Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
July 2022
in “
Journal of Clinical Oncology
”
TLDR Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
The study compared oral paclitaxel plus encequidar (oPac + E) to intravenous paclitaxel (IVpac) in 402 women with metastatic breast cancer. Results showed that oPac + E had a higher confirmed tumor response rate (36% vs. 23%) and longer median progression-free survival (8.4 months vs. 7.4 months) compared to IVpac. Overall survival was also longer for oPac + E (22.7 months vs. 16.5 months). While both treatments had similar rates of grade 3-4 adverse reactions, oPac + E had lower rates of neuropathy and alopecia but higher rates of gastrointestinal toxicity and neutropenic complications. The study concluded that oPac + E increased tumor response and had less neuropathy but more serious infections compared to IVpac.
